Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
Umemoto K, Takahashi H, Morizane C, Yamada I, Shimizu S, Shioji K, Yoshida Y, Motoya M, Mizuno N, Kojima Y, Terashima T, Uesugi K, Ueno M, Furuse J, Akimoto T, Ikeda M. Umemoto K, et al. Among authors: motoya m. Cancer Chemother Pharmacol. 2021 Mar;87(3):397-404. doi: 10.1007/s00280-020-04206-w. Epub 2021 Jan 2. Cancer Chemother Pharmacol. 2021. PMID: 33386925 Free PMC article.
Recent advancements in image-enhanced endoscopy in the pancreatobiliary field.
Toyonaga H, Hayashi T, Hama K, Ando R, Ishii T, Yoshida K, Kin T, Motoya M, Takahashi K, Katanuma A. Toyonaga H, et al. Among authors: motoya m. DEN Open. 2024 May 14;5(1):e382. doi: 10.1002/deo2.382. eCollection 2025 Apr. DEN Open. 2024. PMID: 38746904 Free PMC article. Review.
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komoto I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobayashi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horiguchi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Senju M, Arioka H, Hara K, Imamura M, Okusaka T. Shibuya H, et al. Among authors: motoya m. Cancer Chemother Pharmacol. 2018 Oct;82(4):661-668. doi: 10.1007/s00280-018-3656-y. Epub 2018 Jul 27. Cancer Chemother Pharmacol. 2018. PMID: 30054710
Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J. Okano N, et al. Among authors: motoya m. Int J Clin Oncol. 2020 Oct;25(10):1835-1843. doi: 10.1007/s10147-020-01721-x. Epub 2020 Jun 13. Int J Clin Oncol. 2020. PMID: 32535711 Clinical Trial.
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. J Gastroenterol Hepatol. 2023 Apr;38(4):556-564. doi: 10.1111/jgh.16066. Epub 2023 Jan 10. J Gastroenterol Hepatol. 2023. PMID: 36403136
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, Kaneto H, Yonezawa K, Yawata A, Adachi T, Hamamoto Y, Shinomura Y. Akutsu N, et al. Among authors: motoya m. Int J Clin Oncol. 2015 Feb;20(1):105-10. doi: 10.1007/s10147-014-0691-5. Epub 2014 Apr 18. Int J Clin Oncol. 2015. PMID: 24744262
Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T, Nakamura T, Kimura Y, Yoshida M, Someya M, Kawakami H, Sakuhara Y, Katoh N, Takahashi K, Ambo Y, Miura K, Motoya M, Tanaka E, Murakawa K, Yamabuki T, Yamazaki H, Katanuma A, Hirano S; Hokkaido Pancreatic Study Group. Hayashi T, et al. Among authors: motoya m. Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):606-617. doi: 10.1016/j.ijrobp.2019.07.004. Epub 2019 Jul 12. Int J Radiat Oncol Biol Phys. 2019. PMID: 31306735 Clinical Trial.
60 results